Phase II study of exemestane (E) in refractory ovarian cancer (ROC).

Abstract

5026 Background: Despite biologic rationale, endocrine therapeutic strategies have been under investigated in ovarian cancer. This is the first study to report the efficacy of an aromatase inhibitor, E, in patients (pts) with ROC. METHODS This was a pilot, phase II, single-centre, non-comparative, open-label study. Pts with ROC stage II - IV who had… (More)

Topics

Cite this paper

@article{Verma2006PhaseIS, title={Phase II study of exemestane (E) in refractory ovarian cancer (ROC).}, author={S. Verma and Maryam Alhayki and T. Le and Kevin H. Baines and Lisa Rambout and L. N. Hopkins and Michael Fung Kee Fung}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2006}, volume={24 18_suppl}, pages={5026} }